Click Holdings Limited (NASDAQ:CLIK) Short Interest Up 913.9% in July

Click Holdings Limited (NASDAQ:CLIK) was the target of a significant increase in short interest in the month of July. As of July 31st, there was short interest totaling 19,660 shares, an increase of 913.9% from the July 15th total of 1,939 shares. Based on an average daily volume of 577,994 shares, the days-to-cover ratio is presently 0.0 days. Approximately 1.7% of the company’s stock are sold short.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on CLIK. Wall Street Zen raised shares of Click to a “hold” rating in a research note on Saturday, June 13th. Weiss Ratings reissued a “sell (d)” rating on shares of Click in a research report on Wednesday, June 24th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has an average rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Click stock. Renaissance Technologies LLC acquired a new stake in Click Holdings Limited (NASDAQ:CLIK) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 14,200 shares of the company’s stock, valued at approximately $25,000. Renaissance Technologies LLC owned approximately 1.23% of Click at the end of the most recent quarter.

Click Trading Down 1.4%

CLIK traded down $0.02 on Tuesday, hitting $1.44. 16,248 shares of the company were exchanged, compared to its average volume of 364,692. The firm has a 50-day moving average price of $1.53 and a two-hundred day moving average price of $2.38. Click has a twelve month low of $1.32 and a twelve month high of $14.40.

Click (NASDAQ:CLIK) last posted its quarterly earnings results on Monday, May 11th. The company reported $0.10 earnings per share (EPS) for the quarter. The company had revenue of $3.79 million during the quarter.

About Click

Click Therapeutics, Inc (NASDAQ: CLIK) is a clinical-stage digital therapeutics company developing software-based treatments for neurological, psychiatric and chronic diseases. Its platform delivers prescription digital therapies via mobile and web applications, combining evidence-based cognitive behavioral interventions, digital monitoring tools and patient engagement techniques. Click’s approach is designed to complement or extend traditional pharmacological and behavioral treatments for conditions such as major depressive disorder, insomnia and tobacco use disorder.

Founded in 2014, Click has progressed multiple programs through randomized controlled trials and regulatory review.